Fundraising Fox
プラチナバイオ株式会社
東広島市, JP · Founded 2019 · 2 known investors
Find your way into プラチナバイオ株式会社
Sign up to see every warm intro you have to プラチナバイオ株式会社
- Paths you didn't know you had: your email and LinkedIn already hold routes to the プラチナバイオ株式会社 team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PtBio develops genome editing technology and bio-DX tools for analyzing the genomes of industrially used organisms, positioning itself as a platform provider. Its applications include allergy-free eggs, CO2-converting microalgae for carbon recycling, advanced medical treatments, resource-recycling agriculture, aquatic resource supply, and bio-manufacturing.
Founders & leadership
プラチナバイオ株式会社 was founded in 2019 by Keisuke Okuhara.
KO
Keisuke OkuharaRepresentative Director & CEOKeisuke Okuhara holds a Master of Science degree and has worked across government agencies before founding PtBio, where he serves as Representative Director and CEO. The company develops genome editing technology and bio-diagnostic tools for industrial organisms, with applications spanning agriculture, pharmaceuticals, and biomanufacturing.
奥啓
奥原 啓輔代表取締役 / Chief Executive Officer
TY
Takashi YamamotoDirector & CTO
AI
Atsuhiro IshiiCOOAtsuhiro Ishii holds a master's degree in Electrical and Electronics Engineering from Keio University with specialization in laser drug delivery, and spent over four years as a consultant at Arthur D. Little before joining PtBio, where he progressed from Business Co-creation Director to COO overseeing business strategy and operations.
HB
Hidemasa BonoCSO (Chief Scientific Officer)Hidemasa Bono holds a Ph.D. in Science from Kyoto University and has held research and faculty positions in genomics at institutions including the RIKEN Yokohama Research Center, Saitama Medical University, and Hiroshima University, where he is currently a professor and deputy director of the Genome Editing Innovation Center.
YK
Yumiko KusakabeChief Strategy OfficerYumiko Kusakabe is Chief Strategy Officer at PtBio, which develops genome editing and bio-diagnostic tools for industrial organisms. She brings 19 years of international banking and emerging markets experience, along with expertise in structured finance, project finance, and open innovation strategy across genomics, biotech, and agritech sectors.
Investors · 2
Frequently asked questions
- What does プラチナバイオ株式会社 do?
- PtBio develops genome editing technology and bio-DX tools for analyzing the genomes of industrially used organisms, positioning itself as a platform provider. Its applications include allergy-free eggs, CO2-converting microalgae for carbon recycling, advanced medical treatments, resource-recycling agriculture, aquatic resource supply, and bio-manufacturing.
- Who founded プラチナバイオ株式会社?
- プラチナバイオ株式会社 was founded by Keisuke Okuhara in 2019.
- Who are プラチナバイオ株式会社's investors?
- プラチナバイオ株式会社's investors include Hiroshima Venture Capital Co. Ltd., Kobe University Capital.
- Where is プラチナバイオ株式会社 headquartered?
- プラチナバイオ株式会社 is headquartered in 東広島市, JP.